Vor Biopharma Inc: 5%+ holders

As of November 8, 2026, 8 holders' latest Schedule 13D or 13G filings report owning 5% or more of Vor Biopharma Inc. The largest reported stake is RA Capital Management, L.P.'s, at 19.9%. 50 filings are on record since July 9, 2025 (Schedule 13D/A, July 21, 2026).

5AM Ventures VI, L.P. also filed stake reports on 2 other companies ↓

Sell to companies like Vor Biopharma Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-11-05 · Reporting person: Fmr LLC · Sole voting: 6,317,873 · Shared voting: 0 · Sole dispositive: 6,318,525 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-05
• Filing 2026-08-14 · Reporting person: Venrock Healthcare Capital Partners III, L.P. · Sole voting: 0 · Shared voting: 5,676,370 · Sole dispositive: 0 · Shared dispositive: 5,676,370 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: Frazier Life Sciences Public Fund, L.P. · Sole voting: 0 · Shared voting: 2,258,001 · Sole dispositive: 0 · Shared dispositive: 2,258,001 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-13 · Reporting person: Verve Capital Limited · Sole voting: 3,410,892 · Shared voting: 0 · Sole dispositive: 3,410,892 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-13
• Filed 2026-08-07 · Holder: Fmr LLC · Percent: 12% · SCHEDULE 13G/A

Vor Biopharma Inc has 50 Schedule 13D or 13G filings on record since 2025-07-09. 8 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Vor Biopharma Inc and the warning signs.

See Vor Biopharma Inc's free Snapshot Watch Vor Biopharma Inc: email me the next time it files something

Free to see. No signup.

Keep reading

More on Vor Biopharma Inc and the records around it.

Vor Biopharma Inc elsewhere on the record

• Who owns it

Companies that share a holder

• 5AM Ventures VI, L.P. also filed stake reports on 2 other companies: CAMP4 THERAPEUTICS CORPORATION (Aug 2026), ARTIVA BIOTHERAPEUTICS, INC. (Aug 2026)
• ForGrowth III PA B.V. also filed stake reports on 4 other companies: Aura Biosciences, Inc. (Oct 2026), Crescent Biopharma, Inc. (Dec 2025), Astria Therapeutics, Inc. (Nov 2025)
• Great Point Partners, LLC also filed stake reports on 14 other companies: LeonaBio, Inc. (Nov 2026), Research Alliance Corporation III (Sep 2026), JATT III Acquisition Corp (Sep 2026)

Want the whole picture on Vor Biopharma Inc?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Vor Biopharma Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Vor Biopharma Inc covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   51 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Vor Biopharma Inc by CUSIP 929033207 and gives its principal executive office as 500 BOYLSTON STREET, SUITE 1350, BOSTON, MA 02116 (SCHEDULE 13G/A, 2026-11-05).

What the percentages are based on

Due to the Beneficial Ownership Blocker listed in the Pre-Funded Warrants, each Reporting Person's beneficial ownership percentage was 9.99% as of June 30, 2026.Venrock Healthcare Capital Partners III, L.P., SCHEDULE 13G/A, 2026-08-14

Source of funds (Item 3)

Item 3 of the Statement is hereby amended and supplemented as follows: On July 16, 2026, the Fund exercised Pre-Funded Warrants to purchase an aggregate of 2,100,000 shares of the Issuer's common stock for $0.002 a share. The Fund exercised the Pre-Funded Warrants on a cashless basis, resulting in the Issuer's withholding of 213 of such shares to satisfy the exercise price of the Pre-Funded Warrants, and the issuance to the Fund of an aggregate of 2,099,787 shares.RA Capital Management, L.P., SCHEDULE 13D/A, 2026-07-21

Purpose of Transaction (Item 4)

Reprogrammed Interchange LLC

Item 4 of Schedule 13D is hereby amended and supplemented as follows: From October 15, 2025 through October 16, 2025, Reprogrammed Interchange LLC sold the following shares of Vor Biopharma Inc. in open market transactions, resulting in a decrease in the number of shares of Common Stock beneficially owned by the Reporting Persons by more than one percent of the outstanding shares of Common Stock of the Issuer. 1. 71,655 shares on October 15, 2025, at a weighted average per share sale price of $31.9196. 2. 2,021 shares on October 16, 2025, at a weighted average per share sale price of $30.4548.Item 4 of the SCHEDULE 13D/A filed 2025-10-17

RA Capital Management, L.P.

Item 4 of the Statement is hereby amended and supplemented as follows: Effective July 6, 2026, Andrew Levin resigned from the Board of Directors of the Issuer.Item 4 of the SCHEDULE 13D/A filed 2026-07-21

ForGrowth III PA B.V.

The Reporting Persons acquired their shares of Common Stock as an investment in the ordinary course of business. On December 18, 2025, Wouter Joustra, a General Partner at Forbion Capital, was appointed to the Issuer's board of directors. The Reporting Persons, either directly or indirectly through Mr. Joustra, may engage in discussions from time to time with the Issuer's board of directors, the Issuer's management or the Issuer's other stockholders. These discussions may be with respect to (i) acquiring or disposing of the shares or other securities of the Issuer; (ii) maintaining or changing the Issuer's business, operations, governance, management, strategy or capitalization; or (iii) implementing transactions that may relate to or may result in any matter set forth in paragraphs (a) through (j) of Item 4 of Schedule 13D. Additionally, the Reporting Persons may acquire additional securities through open market transactions, privately negotiated transactions or other methods. In connection with the foregoing, and as may be appropriate from time to time, each of the Reporting Persons may consider the feasibility and advisability of various alternative courses of action with respect to their investment in the Issuer, including, without limitation: (a) the acquisition or disposition by the Reporting Persons of the shares, including through derivative transactions which may include security-based swaps and short sales; (b) an extraordinary corporate transaction, such as a …The first part of Item 4 of the SCHEDULE 13D filed 2025-12-23; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Vor Biopharma Inc

Who owns Vor Biopharma Inc?

On this page, 8 holders' latest ownership filings report 5% or more of Vor Biopharma Inc: RA Capital Management, L.P. (19.9%, Schedule 13D/A, filed 2026-07-21), Reprogrammed Interchange LLC (17.6%, Schedule 13D/A, filed 2025-10-17), Fmr LLC (10.7%, Schedule 13G/A, filed 2026-11-05), Chen Yu (10.5%, Schedule 13G, filed 2026-04-01) and ForGrowth III PA B.V. (9.99%, Schedule 13D, filed 2025-12-23); 3 more are listed above.

Who are the largest shareholders of Vor Biopharma Inc?

By the share each holder's latest filing reports, the largest holders of Vor Biopharma Inc on this page are RA Capital Management, L.P. (19.9%), Reprogrammed Interchange LLC (17.6%) and Fmr LLC (10.7%).

When did RA Capital Management, L.P. buy into Vor Biopharma Inc?

The filings give report dates, not purchase dates. The earliest filing from RA Capital Management, L.P. on this page is the Schedule 13D/A, filed 2025-09-19, reporting 29%; its latest, Schedule 13D/A filed 2026-07-21, reports 19.9%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 50 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Vor Biopharma Inc

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Vor Biopharma Inc. With no account yet, you sign up free and land on the result.

• Get an alert when Vor Biopharma Inc is mentioned again
• Find former Vor Biopharma Inc employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes